Anti-VEGF agents and the risk of arteriothrombotic events

Keyphrases

• Anti-vascular Endothelial Growth Factor (anti-VEGF) 100%
• Serious Adverse Events 66%
• High Risk 66%
• Vascular Endothelial Growth Factor 66%
• Vascular Endothelial Growth Factor Signaling 66%
• Diabetic Macular Edema 66%
• Systemic Complications 66%
• Intravitreal Anti-vascular Endothelial Growth Factor Injection 66%
• All-cause Mortality 33%
• Hypertension 33%
• Cancer Treatment 33%
• Nitric Oxide 33%
• Pharmacokinetics 33%
• Tyrosine Kinase 33%
• Sequestration 33%
• Thrombosis 33%
• Systemic Administration 33%
• Intravitreal Injection 33%
• Vascular Endothelial Cells 33%
• Design Requirements 33%
• Systemic Circulation 33%
• Factor Level 33%
• Randomized Control 33%
• Enrollment Criteria 33%
• Neovascular Age-related Macular Degeneration (nAMD) 33%
• Drug Clearance 33%
• Aflibercept 33%
• Intravitreal Ranibizumab 33%
• Ranibizumab Injection 33%
• Low-frequency Events 33%
• Multiple Strokes 33%
• Endothelial Cell Death 33%
• Plasma Vascular Endothelial Growth Factor 33%
• Prostaglandin I 2 33%
• Intravitreal Aflibercept Injection 33%

Medicine and Dentistry

• Vasculotropin 100%
• Adverse Event 20%
• Apoplexy 20%
• Diabetic Macular Edema 20%
• Aflibercept 20%
• All Cause Mortality 10%
• Nitric Oxide 10%
• Cancer Therapy 10%
• Pharmacokinetics 10%
• Protein Tyrosine Kinase 10%
• Cell Death 10%
• Thrombosis 10%
• Systemic Administration 10%
• Intravitreal Administration 10%
• Vascular Endothelial Cell 10%
• Systemic Circulation 10%
• Bevacizumab 10%
• Wet Macular Degeneration 10%
• Ranibizumab 10%
• Drug Clearance 10%
• Prostacyclin Derivative 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Vasculotropin 100%
• Adverse Event 20%
• Diabetic Macular Edema 20%
• Aflibercept 20%
• All Cause Mortality 10%
• Malignant Neoplasm 10%
• Nitric Oxide 10%
• Pharmacokinetics 10%
• Protein Tyrosine Kinase 10%
• Systemic Administration 10%
• Thrombosis 10%
• Systemic Circulation 10%
• Bevacizumab 10%
• Prostacyclin Derivative 10%
• Intravitreal Administration 10%
• Ranibizumab 10%
• Wet Macular Degeneration 10%